6-hydrazinyl-N-methylpyridine-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-hydrazinyl-N-methylpyridine-3-carboxamide
• 化学式: C₇H₁₀N₄O
• 分子量: 166.18
• InChiKey: GSRZVAGTAJGFRZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  80
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY
  申请人：Technische Universität München

  公开号：EP3494999A1

  公开（公告）日：2019-06-12

  The present disclosure relates to imaging and endoradiotherapy of diseases involving prostate-specific membrane antigen (PSMA). Provided are compounds which bind or inhibit PSMA and furthermore carry at least one moiety which is amenable to radiolabeling. Provided are also medical uses of such compounds.

  本公开涉及涉及前列腺特异性膜抗原（PSMA）相关疾病的成像和内放射治疗。提供了结合或抑制PSMA并且携带至少一个适合于放射标记的基团的化合物。还提供了这类化合物的医疗用途。
• GLYCOSYLATED PSMA INHIBITORS FOR IMAGING AND ENDORADIOTHERAPY
  申请人：Technische Universität München

  公开号：EP3494998A1

  公开（公告）日：2019-06-12

  The present disclosure relates to imaging and endoradiotherapy of diseases involving prostate-specific membrane antigen (PSMA). Provided are compounds which bind or inhibit PSMA and furthermore carry at least one moiety which is amenable to radiolabeling. Provided are also medical uses of such compounds.

  本公开涉及涉及前列腺特异性膜抗原（PSMA）相关疾病的成像和内放射治疗。提供了结合或抑制PSMA并且携带至少一个适合于放射标记的基团的化合物。还提供了这类化合物的医学用途。
• [EN] PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY<br/>[FR] LIGANDS DE PSMA POUR L'IMAGERIE ET L'ENDORADIOTHÉRAPIE
  申请人：UNIV MUENCHEN TECH

  公开号：WO2019115547A1

  公开（公告）日：2019-06-20

  The present disclosure relates to imaging and endoradiotherapy of diseases involving prostate-specific membrane antigen (PSMA). Provided are compounds which bind or inhibit PSMA and furthermore carry at least one moiety which is amenable to radiolabeling. Provided are also medical uses of such compounds.

  本公开涉及涉及前列腺特异性膜抗原（PSMA）相关疾病的成像和内放射治疗。提供了结合或抑制PSMA并且携带至少一个适合于放射标记的基团的化合物。还提供了这类化合物的医疗用途。
• [EN] CXCR4-TARGETED DIAGNOSTIC AND THERAPEUTIC AGENTS WITH REDUCED SPECIES SELECTIVITY<br/>[FR] AGENTS THÉRAPEUTIQUES ET DIAGNOSTIQUES DIRIGÉS CONTRE LE CXCR4 À SÉLECTIVITÉ D'ESPÈCES RÉDUITE
  申请人：UNIV MUENCHEN TECH

  公开号：WO2020053256A1

  公开（公告）日：2020-03-19

  The present disclosure relates to imaging and endoradiotherapy of diseases involving chemokine receptor 4 (CXCR4). Provided are compounds which bind or inhibit hCXCR4 and mCXCR4 and furthermore carry at least one moiety which is amenable to labeling. Provided are also medical uses of such compounds.

  本公开涉及与化学因子受体4（CXCR4）有关的疾病的成像和内部放射治疗。提供了结合或抑制hCXCR4和mCXCR4的化合物，而且这些化合物还携带至少一个适合标记的基团。还提供了这些化合物的医疗用途。
• [EN] CANCER DIAGNOSTIC IMAGING AGENTS<br/>[FR] AGENTS D'IMAGERIE POUR LE DIAGNOSTIC DU CANCER
  申请人：TECHNISCHE UNIVERSITÄT MÜNCHEN

  公开号：WO2020157184A1

  公开（公告）日：2020-08-06

  The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within a single molecule three separate moieties: (a) one or more ligands which are capable of binding to PSMA, (b) a silicon-fluoride acceptor (SIFA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom, and (c) one or more chelating groups, containing a chelated nonradioactive cation.

  本发明涉及一种配体-SIFA-螯合物共轭物，包括在一个分子内的三个单独的部分：(a) 一个或多个能够结合到PSMA的配体，(b) 一个硅氟受体(SIFA)部分，其中包括硅原子和氟原子之间的共价键，以及(c) 一个或多个螯合基团，含有螯合的非放射性阳离子。